Conclusion: OS and PFS outcomes were superior to those observed in prior studies evaluating sorafenib alone in patients with a similar disease status, warranting further study of this treatment combination.
://www.dovepress.com/yttrium-90-resin-microspheres-as-an-adjunct-to-sorafenib-in-patients-w-peer-reviewed-article-JHC
- Forums
- ASX - By Stock
- SRX
- Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellula
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellula
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M |
Open | High | Low | Value | Volume |
17.5¢ | 17.8¢ | 17.5¢ | $68.91K | 393.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3966005 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 2611882 | 37 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3966005 | 0.175 |
6 | 1607688 | 0.170 |
1 | 18186 | 0.165 |
1 | 2577 | 0.097 |
1 | 4000 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 1957882 | 33 |
0.185 | 100499 | 6 |
0.190 | 185422 | 8 |
0.195 | 520478 | 3 |
0.200 | 187653 | 8 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |